Development of Secondary Resistance to Fluconazole in Cryptococcus neoformans Isolated from a Patient with AIDS

Cryptococcus neoformans is the fifth most common opportunistic agent of infection in patients with AIDS in the USA, exceeded only by Candida species, Pneumocystis carinii, cytomegalovirus and Mycobacterium avium1, 2, 6, 10, 11. In Brazil is the sixth, exceeded by Candida species, P. carinii, Mycobac...

Full description

Bibliographic Details
Published in:Revista do Instituto de Medicina Tropical de São Paulo
Main Authors: Sydney H. ALVES, Jorge O. LOPES, Jane M. COSTA, Clóvis KLOCK
Format: Article in Journal/Newspaper
Language:English
Published: Universidade de São Paulo (USP) 1997
Subjects:
Cryptococcus neoformans
Secondary resistance
Fluconazole
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Sida
Online Access:https://doi.org/10.1590/S0036-46651997000600010
https://doaj.org/article/a22479f2b0394d6fb7a79beb0df0da3c
Description
Summary:Cryptococcus neoformans is the fifth most common opportunistic agent of infection in patients with AIDS in the USA, exceeded only by Candida species, Pneumocystis carinii, cytomegalovirus and Mycobacterium avium1, 2, 6, 10, 11. In Brazil is the sixth, exceeded by Candida species, P. carinii, Mycobacterium species, Toxoplasma gondii, and herpes simplex virus (AIDS, Boletim Epidemiológico, set/nov 96, Ministério da Saúde, Brasil). During 30 years, the treatment of C. neoformans meningitis was based on the use of amphotericin B with or without flucytosine13. Nowadays, with the immunodepression caused by human immunodeficiency virus (HIV) infection and the availability of new antifungal drugs as the triazoles, the concept related to cure and relapses of cryptococcosis has been altered7, 20. Patients are treated with amphotericin B with or without flucytosine as initial therapy, but maintenance therapy is always necessary in AIDS patients with C. neoformans infections Relatamos um caso de meningite por Cryptococcus neoformans em paciente com Síndrome de Imunodeficiência Adquirida (SIDA). A terapia de manutenção com fluconazol não evidenciou melhora clínica e micológica, ao mesmo tempo em que o teste de suscetibilidade in vitro revelou aumento progressivo da concentração inibitória mínima (CIM). Estes resultados sugerem o desenvolvimento de resistência secundária ao fluconazol, todavia, resistência cruzada com outros derivados azólicos não foi constatada

Similar Items